A group of familiar faces to Incyte watchers has broken off to start their own biotech, pulling in $102 million to develop competitors to approved cancer drugs from AstraZeneca, GSK, Novartis and ...
HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus radiation therapy (RT), a small phase I ...
Synnovation Therapeutics Inc. has patented phosphatidylinositol 3-kinase α (PI3K-α) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum and CLOVES syndrome ...
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. There are several clinical trials that are ...
Researchers at the School of Pharmacy and Biomolecular Sciences from the Royal College of Surgeons in Ireland and collaborating institutions have detailed the design, synthesis and biological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results